BiotechTube
Shinpoong Pharm

Shinpoong Pharm

019170.KSPre-clinical
Seoul, South KoreaFounded 1962100-500 employeesshinpoong.co.kr

Shinpoong Pharm is a public South Korean pharmaceutical company with a strategic focus on anti-infectives, especially for malaria and neglected tropical diseases. Its flagship product, Pyramax, is a WHO-prequalified artemisinin-based combination therapy (ACT) for malaria, representing a significant commercial and public health achievement. The company is expanding its pipeline through internal R&D and partnerships, aiming to solidify its position as a key player in global infectious disease therapeutics. Its operations span development, manufacturing, and commercialization, with a strong emphasis on markets in Asia and Africa.

Market Cap
$359.4M
+36.8% period
Pipeline
—
Patents
—
Publications
1
indexed

019170.KS · Stock Price

USD 10930.00+2940.00 (+36.80%)

Historical price data

AI Company Overview

Shinpoong Pharm is a public South Korean pharmaceutical company with a strategic focus on anti-infectives, especially for malaria and neglected tropical diseases. Its flagship product, Pyramax, is a WHO-prequalified artemisinin-based combination therapy (ACT) for malaria, representing a significant commercial and public health achievement. The company is expanding its pipeline through internal R&D and partnerships, aiming to solidify its position as a key player in global infectious disease therapeutics. Its operations span development, manufacturing, and commercialization, with a strong emphasis on markets in Asia and Africa.

Infectious DiseasesMalariaNeglected Tropical Diseases

Technology Platform

Specialization in the development, formulation, and global registration of fixed-dose combination therapies for infectious diseases, particularly artemisinin-based combination therapies (ACTs) for malaria.

Funding History

1
IPOUndisclosedJun 15, 1990

Opportunities

Significant growth opportunity exists in expanding the use of Pyramax for malaria chemoprevention (SMC), a large and recurring public health market.
Further opportunities include geographic expansion into new endemic regions and portfolio diversification into other neglected tropical diseases through partnerships or internal R&D.

Risk Factors

Key risks include heavy dependence on a single product (Pyramax) and volatile revenue streams tied to winning large, competitive global health tenders.
The company also faces intense price pressure in the generic ACT market and regulatory risks associated with maintaining WHO prequalification status.

Competitive Landscape

Shinpoong competes primarily with other manufacturers of WHO-prequalified artemisinin-based combination therapies (ACTs), including Novartis (Coartem), Sanofi, and several Indian and Chinese generic drug makers. Its differentiation is based on Pyramax's efficacy against both major malaria parasites, a favorable safety profile, and a pediatric-friendly formulation.